{"ATC Code":"R06AE07","Abbreviation":"","Aliases":["Cetirizina","Cetryn","Ziptek","Setir","Cetirizinum","Cetirizin","Hitrizin Film Tablet","(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid","(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid","Acetic acid, (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-"],"Biological Half-Life":"Plasma elimination half-life is 8.3 hours.","CAS":"83881-51-0","ChEBI":"CHEBI:3561","ChEMBL":"CHEMBL1000","ChemicalClasses":["carboxylic acid"],"Chirality":"racemic","Classes":null,"Color/Form":"Crystals from ethanol","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antihistamines","Drug Indication":"**Seasonal Allergic Rhinitis**: Indicated for the relief of symptoms associated with seasonal allergic rhinitis caused by allergens such as ragweed, grass and tree pollens in adults and children 2 years of age and above. Symptoms treated effectively include sneezing, rhinorrhea, nasal pruritus, ocular pruritus, tearing, and redness of the eyes.   **Perennial allergic rhinitis**: This drug is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens including dust mites, animal dander, and molds in adults and children 6 months of age and older. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing.   **Chronic urticaria**: Cetirizine is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. It markedly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus.","Drug Warnings":"In a controlled study of 1 week's duration in patients 6-11 months of age, those receiving cetirizine exhibited greater irritability/fussiness than those receiving placebo. In a controlled study in patients 12 months of age and older, insomnia occurred more frequently with cetirizine than with placebo (9 vs 5.3%, respectively). In those who received 5 mg or more daily, fatigue occurred in 3.6 or 1.3% and malaise in 3.5 or 1.8% of those receiving cetirizine or placebo, respectively.","DrugClasses":[],"DurationOfAction":"≥24 hours","EliminationHalfLife":"Mean: 8.3 hoursRange: 6.5 – 10 hours\u003ca href='#cite_note-6'\u003e\u003csup\u003e[6]\u003c/sup\u003e\u003c/a\u003e","Erowid Experience Reports":[],"European Community (EC) Number":"695-115-1","FDA Pharmacological Classification":"YO7261ME24","FullSalts":["Cetirizine hydrochloride"],"HMDB ID":"HMDB0005032","HeavyAtomCount":27,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antihistamines","IUPACName":"2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid","InChI":"InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)","InChIKey":"ZKLPARSLTMPFCP-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)","Melting Point":"110-115°C","MolecularFormula":"C\u003csub\u003e21\u003c/sub\u003eH\u003csub\u003e25\u003c/sub\u003eClN\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e3\u003c/sub\u003e","MolecularWeight":"388.9 g/mol","Opticalactivity":"( + / - )","Pharmacodynamics":"**General effects and respiratory effects**  Cetirizine, the active metabolite of the piperazine H\u003csub\u003e1\u003c/sub\u003e-receptor antagonist hydroxyzine, minimizes or eliminates the symptoms of chronic idiopathic urticaria, perennial allergic rhinitis, seasonal allergic rhinitis, allergic asthma, physical urticaria, and atopic dermatitis. The clinical efficacy of cetirizine for allergic respiratory diseases has been well established in numerous trials.   **Effects on urticaria/anti-inflammatory effects**  It has anti-inflammatory properties that may play a role in asthma management. There is evidence that cetirizine improves symptoms of urticaria. Marked clinical inhibition of a wheal and flare response occurs in infants, children as well as adults within 20 minutes of one oral dose and lasts for 24 h.  Concomitant use of cetirizine reduces the duration and dose of topical anti-inflammatory formulas used for the treatment of atopic dermatitis.","Physical Description":"Solid","PrevSalts":["hydrochloride"],"PubChemId":2678,"Record Description":["Cetirizine is a member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively. It has a role as an anti-allergic agent, a H1-receptor antagonist, an environmental contaminant and a xenobiotic. It is a monocarboxylic acid, a member of piperazines, a member of monochlorobenzenes and an ether.","Cetirizine, also commonly known as Zyrtec, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,.   One of the most common uses for this drug is for a condition called allergic rhinitis. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals. Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects.   Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor without sedating effects.","Cetirizine is a Histamine-1 Receptor Antagonist. The mechanism of action of cetirizine is as a Histamine H1 Receptor Antagonist.","Cetirizine is cetirizine is a metabolite of hydroxyzine and a selective peripheral histamine H1-receptor antagonist. It is used for symptomatic treatment of seasonal and perennial allergic rhinitis and for chronic urticaria. (NCI)","CETIRIZINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 9 approved and 17 investigational indications.","Cetirizine is a medication used for the treatment of allergies, hay fever, angioedema, and hives. It is a second-generation H1-receptor antagonist antihistamine and works by blocking H1 histamine receptors. It is a major metabolite of hydroxyzine, and has the same basic side effects, including dry mouth. A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects. Cetirizine hydrochloride is a medication used for the treatment of allergies, hay fever, angioedema, and hives. It is a second-generation H1-receptor antagonist antihistamine and works by blocking H1 histamine receptors. It is a major metabolite of hydroxyzine, and has the same basic side effects, including dry mouth.","A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.","See also: Cetirizine Hydrochloride (has salt form).","Cetirizine is a member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively. It has a role as an anti-allergic agent, a H1-receptor antagonist, an environmental contaminant and a xenobiotic. It is a monocarboxylic acid, a member of piperazines, a member of monochlorobenzenes and an ether.","LiverTox|Respiratory|Allergy symptoms|Antihistamine"],"RefCount":7,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Cetirizine","Name":"Cetirizine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q423075","Name":"Cetirizine","Sub":false},{"Link":"https://www.wikidata.org/wiki/Q27459023","Name":"(+)-Cetirizine","Sub":true}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00341","Name":"Cetirizine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/2678","Name":"Cetirizine","Sub":false},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/150716","Name":"(+)-Cetirizine","Sub":true}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1000","Name":"Cetirizine","Sub":false},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1334217","Name":"(+)-Cetirizine","Sub":true}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3561","Name":"Cetirizine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=83881-51-0","Name":"Cetirizine","Sub":false},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=130018-76-7","Name":"(+)-Cetirizine","Sub":true}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0005032","Name":"Cetirizine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07778","Name":"Cetirizine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/YO7261ME24","Name":"Cetirizine","Sub":false},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/V57G6B5I8Z","Name":"(+)-Cetirizine","Sub":true}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID4022787","Name":"Cetirizine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 2678, Cetirizine. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/2678\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/2678\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Cetirizine. UNII: YO7261ME24. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/YO7261ME24\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/YO7261ME24\u003c/a\u003e","Reactine Product information. January 24, 2007. Accessed June 26, 2025. \u003ca href=https://health-products.canada.ca/dpd-bdpp/info?lang=eng\u0026code=46803\u003ehttps://health-products.canada.ca/dpd-bdpp/info?lang=eng\u0026code=46803\u003c/a\u003e","Reactine Product information. August 4, 1997. Accessed June 26, 2025. \u003ca href=https://health-products.canada.ca/dpd-bdpp/info?lang=eng\u0026code=11590\u003ehttps://health-products.canada.ca/dpd-bdpp/info?lang=eng\u0026code=11590\u003c/a\u003e","Zyrtec Product information. July 5, 2001. Accessed June 26, 2025. \u003ca href=https://health-products.canada.ca/dpd-bdpp/info?lang=eng\u0026code=43974\u003ehttps://health-products.canada.ca/dpd-bdpp/info?lang=eng\u0026code=43974\u003c/a\u003e","Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. The American Journal of Medicine. December 1, 2002; 113(Suppl 9A):38S–46S."],"SMILES":"C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl","Salts":["hydrochloride"],"SaltsAcidCount":[2],"SaltsAmineCount":[1],"SaltsUNII":["64O047KTOA"],"Scheduling":[{"gov":"Australia","ref":[],"schedule":"Unscheduled substance"},{"gov":"Canada","ref":["3","4","5"],"schedule":"OTC substance"},{"gov":"New Zealand","ref":[],"schedule":"OTC substance"},{"gov":"United Kingdom","ref":[],"schedule":"GSL substance"},{"gov":"United States","ref":[],"schedule":"OTC substance"}],"StereoisomerRacemic":"(RS)-Cetirizine","Stereoisomers":["(+)-Cetirizine"],"StereoisomersUNII":["V57G6B5I8Z"],"StoreUNII":["YO7261ME24"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="141.3mm" version="1.2" viewBox="0 0 156.365 141.3" width="156.365mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="142.0" stroke="none" width="157.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="73.118" x2="86.32" y1="64.043" y2="71.674"/>
                  
            <line class="bond" id="mol1bnd2" x1="86.32" x2="86.321" y1="71.674" y2="83.072"/>
                  
            <line class="bond" id="mol1bnd3" x1="83.169" x2="73.123" y1="88.742" y2="94.54"/>
                  
            <line class="bond" id="mol1bnd4" x1="73.123" x2="59.921" y1="94.54" y2="86.91"/>
                  
            <line class="bond" id="mol1bnd5" x1="59.921" x2="59.919" y1="86.91" y2="75.511"/>
                  
            <line class="bond" id="mol1bnd6" x1="73.118" x2="63.072" y1="64.043" y2="69.841"/>
                  
            <line class="bond" id="mol1bnd7" x1="56.765" x2="46.72" y1="69.841" y2="64.041"/>
                  
            <line class="bond" id="mol1bnd8" x1="46.72" x2="46.72" y1="64.041" y2="48.801"/>
                  
            <line class="bond" id="mol1bnd9" x1="46.72" x2="36.797" y1="48.801" y2="43.072"/>
                  
            <line class="bond" id="mol1bnd10" x1="33.522" x2="33.522" y1="37.26" y2="25.941"/>
                  
            <line class="bond" id="mol1bnd11" x1="33.522" x2="20.324" y1="25.941" y2="18.321"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="19.104" x2="19.104" y1="19.025" y2="7.002"/>
                        
                <line x1="21.543" x2="21.543" y1="19.025" y2="7.002"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="19.104" x2="19.104" y1="7.001999999999999" y2="13.013499999999999"/>
                <line class="hi" stroke="#FF0D0D" x1="21.543" x2="21.543" y1="7.001999999999999" y2="13.013499999999999"/>
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="20.324" x2="10.404" y1="18.321" y2="24.048"/>
                  
            <line class="bond" id="mol1bnd14" x1="89.475" x2="99.52" y1="88.743" y2="94.542"/>
                  
            <line class="bond" id="mol1bnd15" x1="99.52" x2="99.52" y1="94.542" y2="109.782"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="112.728" x2="99.52" y1="117.402" y2="109.782"/>
                        
                <line x1="110.29" x2="99.52" y1="118.811" y2="112.597"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="112.728" x2="112.728" y1="117.402" y2="132.642"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="99.52" x2="112.728" y1="140.262" y2="132.642"/>
                        
                <line x1="99.52" x2="110.29" y1="137.447" y2="131.234"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="99.52" x2="86.312" y1="140.262" y2="132.642"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="86.312" x2="86.312" y1="117.402" y2="132.642"/>
                        
                <line x1="88.751" x2="88.751" y1="118.811" y2="131.234"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="99.52" x2="86.312" y1="109.782" y2="117.402"/>
                  
            <line class="bond" id="mol1bnd22" x1="99.52" x2="112.719" y1="94.542" y2="86.922"/>
                  
            <g class="bond" id="mol1bnd23">
                        
                <line x1="112.719" x2="125.782" y1="86.922" y2="94.441"/>
                        
                <line x1="115.159" x2="125.788" y1="85.513" y2="91.63"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd24" x1="125.782" x2="139.019" y1="94.441" y2="86.887"/>
                  
            <g class="bond" id="mol1bnd25">
                        
                <line x1="139.019" x2="139.279" y1="86.887" y2="71.765"/>
                        
                <line x1="136.605" x2="136.817" y1="85.457" y2="73.154"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd26" x1="139.279" x2="125.976" y1="71.765" y2="64.032"/>
                  
            <g class="bond" id="mol1bnd27">
                        
                <line x1="125.976" x2="112.74" y1="64.032" y2="71.586"/>
                        
                <line x1="125.965" x2="115.176" y1="66.846" y2="73.003"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd28" x1="112.719" x2="112.74" y1="86.922" y2="71.586"/>
                  
            <line class="bond" id="mol1bnd29" x1="139.279" x2="149.582" y1="71.765" y2="65.954"/>
                  
            <path class="atom" d="M88.263 89.372h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" fill="#3050F8" id="mol1atm3" stroke="none"/>
                  
            <path class="atom" d="M61.859 74.111h-.72l-2.62 -4.066h-.029q.011 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.607 4.055h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" fill="#3050F8" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M35.781 41.178q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM31.917 41.178q.0 .923 .387 1.459q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.929 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.227 .524q-.393 .523 -.393 1.452z" id="mol1atm9" stroke="none"/>
                  
            <path class="atom" d="M22.583 3.078q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.757 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.251 -.566 .757 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM18.719 3.078q.0 .923 .387 1.459q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.227 .524q-.393 .523 -.393 1.452z" id="mol1atm12" stroke="none"/>
                  
            <g class="atom" id="mol1atm13">
                        
                <path d="M9.385 25.938q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 -.0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM5.521 25.938q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M4.305 28.391h-.62v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.62v4.9z" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M153.048 62.302q-.786 -.0 -1.238 .53q-.453 .523 -.453 1.446q.0 .911 .417 1.447q.423 .53 1.268 .53q.321 -.0 .607 -.054q.292 -.059 .566 -.143v.536q-.274 .101 -.566 .149q-.291 .053 -.696 .053q-.744 .0 -1.25 -.309q-.501 -.31 -.751 -.875q-.25 -.572 -.25 -1.34q.0 -.744 .268 -1.309q.274 -.566 .804 -.882q.53 -.321 1.28 -.321q.78 .0 1.351 .286l-.244 .524q-.226 -.102 -.506 -.185q-.274 -.083 -.607 -.083zM155.805 66.725h-.602v-5.215h.602v5.215z" fill="#1FF01F" id="mol1atm27" stroke="none"/>
                
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="86.321" x2="86.3205" y1="83.072" y2="77.373"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="83.169" x2="78.146" y1="88.742" y2="91.641"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="59.919" x2="59.92" y1="75.511" y2="81.2105"/>
            <line class="hi" id="mol1bnd6" stroke="#3050F8" x1="63.072" x2="68.095" y1="69.841" y2="66.94200000000001"/>
            <line class="hi" id="mol1bnd7" stroke="#3050F8" x1="56.765" x2="51.7425" y1="69.841" y2="66.941"/>
            <line class="hi" id="mol1bnd9" stroke="#FF0D0D" x1="36.797" x2="41.7585" y1="43.072" y2="45.9365"/>
            <line class="hi" id="mol1bnd10" stroke="#FF0D0D" x1="33.522" x2="33.522" y1="37.26" y2="31.600499999999997"/>
            <line class="hi" id="mol1bnd13" stroke="#FF0D0D" x1="10.404" x2="15.364" y1="24.048" y2="21.1845"/>
            <line class="hi" id="mol1bnd13" stroke="#FF0D0D" x1="10.404" x2="15.364" y1="24.048" y2="21.1845"/>
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="89.475" x2="94.4975" y1="88.743" y2="91.6425"/>
            <line class="hi" id="mol1bnd29" stroke="#1FF01F" x1="149.582" x2="144.4305" y1="65.954" y2="68.8595"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Therapeutic Uses":"Cetirizine alone or in fixed combination with pseudoephedrine hydrochloride is used for self-medication to provide symptomatic relief of seasonal allergic rhinitis (e.g., hay fever) or other upper respiratory allergies. Cetirizine alone or in fixed combination with pseudoephedrine hydrochloride also is used for the symptomatic treatment of perennial allergic rhinitis. It is recommended that the fixed combination generally be used only when both the antihistamine and nasal decongestant activity of the combination preparation are needed concurrently. /Included in US product label/","Title":"Cetirizine","UNII":"YO7261ME24","Wikidata":"Q423075","Wikipedia":"Cetirizine","XLogP":1.7}